Knight Therapeutics Inc. KHTRF
OTC PK
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -5.54% | -3.71% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.54% | -3.71% | |||
| Cost of Revenue | -8.14% | -6.80% | |||
| Gross Profit | -2.74% | -0.17% | |||
| SG&A Expenses | 3.41% | 5.40% | |||
| Depreciation & Amortization | 8.86% | -9.09% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.33% | -2.77% | |||
| Operating Income | -38.80% | -16.05% | |||
| Income Before Tax | -128.78% | -114.70% | |||
| Income Tax Expenses | -271.68% | 23.07% | |||
| Earnings from Continuing Operations | 21.11% | -125.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 21.11% | -125.30% | |||
| EBIT | -38.80% | -16.05% | |||
| EBITDA | -10.39% | -11.27% | |||
| EPS Basic | 21.05% | -125.33% | |||
| Normalized Basic EPS | -37.16% | -53.84% | |||
| EPS Diluted | 13.36% | -126.05% | |||
| Normalized Diluted EPS | -37.16% | -53.64% | |||
| Average Basic Shares Outstanding | 0.04% | -0.26% | |||
| Average Diluted Shares Outstanding | 0.04% | -0.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||